AMENDMENT NO. 1 TO THE COMMON STOCK PURCHASE AGREEMENTCommon Stock Purchase Agreement • May 15th, 2018 • Rezolute, Inc. • Pharmaceutical preparations
THIS AMENDMENT NO. 1 (the “Amendment”) TO THE COMMON STOCK PURCHASE AGREEMENT dated December 6, 2017 (the “Agreement”) is entered into as of March 30, 2018, by and among Rezolute, Inc., a Delaware corporation (formerly known as AntriaBio, Inc.) (the “Company”), and XOMA Corporation, a Delaware corporation (“Purchaser”). Terms used but not otherwise defined herein shall have the meanings ascribed to them in the Agreement.
AMENDMENT NO. 1 TO THE LICENSE AGREEMENTLicense Agreement • May 15th, 2018 • Rezolute, Inc. • Pharmaceutical preparations
THIS AMENDMENT NO. 1 (the “Amendment”) to the LICENSE AGREEMENT dated as of December 6, 2017 (the “License Agreement”), is entered into on March 30, 2018 (the “Amendment Date”) between XOMA (US) LLC, a Delaware limited liability company, having an address of 2200 Powell Street, Suite 310, Emeryville, CA 94608 (“XOMA”), and Rezolute, Inc., a Delaware corporation, having an address of 1450 Infinite Drive, Louisville, CO 80027 (“Rezolute”). Terms used but not otherwise defined herein shall have the meanings ascribed to them in the License Agreement.
